Amexdrug Corporation
AXRX
$0.0021
$0.00015.00%
| 06/30/2013 | 03/31/2013 | 12/31/2012 | 09/30/2012 | 06/30/2012 | |
|---|---|---|---|---|---|
| Revenue | -6.96% | 8.25% | -12.67% | -30.05% | -36.08% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -6.96% | 8.25% | -12.67% | -30.05% | -36.08% |
| Cost of Revenue | -12.72% | 1.20% | -20.21% | -30.37% | -37.61% |
| Gross Profit | 39.43% | 43.84% | 287.66% | -27.28% | -20.38% |
| SG&A Expenses | 20.27% | 28.81% | -5.79% | -3.92% | 0.99% |
| Depreciation & Amortization | 608.00% | 608.00% | 365.38% | 47.06% | 108.33% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.21% | 4.54% | -18.80% | -28.66% | -35.44% |
| Operating Income | 77.02% | 52.33% | 72.85% | -60.36% | -53.17% |
| Income Before Tax | 78.09% | 51.21% | 68.21% | -64.00% | -54.44% |
| Income Tax Expenses | 238.18% | 26.75% | 96.14% | -77.98% | -75.93% |
| Earnings from Continuing Operations | 36.88% | 65.51% | 53.93% | -56.48% | -40.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.88% | 65.51% | 53.93% | -56.48% | -40.84% |
| EBIT | 77.02% | 52.33% | 72.85% | -60.36% | -53.17% |
| EBITDA | 98.10% | 60.36% | 76.42% | -59.09% | -51.69% |
| EPS Basic | 50.00% | 66.67% | 53.85% | -60.00% | -50.00% |
| Normalized Basic EPS | 50.00% | 50.00% | 66.67% | -60.00% | -50.00% |
| EPS Diluted | 50.00% | 66.67% | 53.85% | -60.00% | -50.00% |
| Normalized Diluted EPS | 50.00% | 50.00% | 66.67% | -60.00% | -50.00% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
